Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Lanying Du and Yuxian He.
Connection Strength

1.377
  1. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antiviral Res. 2020 07; 179:104820.
    View in: PubMed
    Score: 0.220
  2. Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J. 2010 Nov 04; 7:299.
    View in: PubMed
    Score: 0.114
  3. A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 2010 Apr; 23(2):211-9.
    View in: PubMed
    Score: 0.109
  4. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009 Oct 10; 393(1):144-50.
    View in: PubMed
    Score: 0.105
  5. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun. 2009 Jul 10; 384(4):486-90.
    View in: PubMed
    Score: 0.103
  6. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009 Mar; 7(3):226-36.
    View in: PubMed
    Score: 0.101
  7. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008 Mar 20; 26(13):1644-51.
    View in: PubMed
    Score: 0.094
  8. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol. 2008 Jan 15; 180(2):948-56.
    View in: PubMed
    Score: 0.094
  9. Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today (Barc). 2008 Jan; 44(1):63-73.
    View in: PubMed
    Score: 0.094
  10. Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun. 2007 Jul 20; 359(1):174-9.
    View in: PubMed
    Score: 0.090
  11. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007 Apr 12; 25(15):2832-8.
    View in: PubMed
    Score: 0.086
  12. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. Virology. 2006 Sep 15; 353(1):6-16.
    View in: PubMed
    Score: 0.084
  13. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine. 2006 Jun 29; 24(26):5498-508.
    View in: PubMed
    Score: 0.083
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.